A diagnostics company developing a precision oncology platform to transform treatment selection and bring novel therapeutics to patients.

The current oncology treatment selection paradigm has remained unchanged for decades, relying primarily on trial and error. Consequetly, patients today are often forced to cycle through several treatments, exposing them to unnecessary delays and side effects. Xilis is developing its patented MicroOrganoSpheres (MOS) technology to screen therapeutic interventions at the individual patient level and guide personalized therapy. Xilis’ MOS platform offers benefits to patients by identifying optimal treatment sooner, to clinicians by supporting their treatment recommendations, and to pharmaceutical companies by validating compounds and allowing them to run clinical trials at lower cost.

No items found.